Ian Mortimer
Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director
Good morning, everyone. My name is Ian Mortimer, I’m the President and CEO of Xenon Pharmaceuticals, and I will be moderating today’s session.
Thank you for joining us on this investor webinar focused on our Kv7 and Nav1.7 programs in the development for the treatment of pain.
Before diving into the speaker introductions and agenda for today, please note the standard notice that we will make a number of statements that are forward-looking. I encourage you to review our SEC filings for a more fulsome discussion of risks facing our business, and readers are cautioned not to place undue reliance on such forward-looking statements.
With that, I’m pleased to introduce my colleagues who are speaking on today’s call. Dr. Jim Empfield, Xenon’s Executive Vice President, Drug Discovery; Dr. JP Gilbert, Xenon’s Senior Director of Biology; and Dr. Chris Kenney, Xenon’s Chief Medical Officer.
To kick us off, I’ll provide a brief corporate overview, including our current pipeline. Jim will then provide some of Xenon’s history and outline the work we’ve done over the years to position Xenon as a leader in ion channel drug development and how that translates specifically to our work in pain. Having spent almost a decade at Xenon, Jim has been integral to the extensive buildout of our discovery function and has an impressive pedigree previously serving as Vice President, Drug Discovery and Chemistry and co-site Head of Research at Vertex in Boston. And prior to that, leading CNS chemistry and various other positions at AstraZeneca.
